Selective Intra-Arterial Lutetium-177-Labeled Prostate-Specific Membrane Antigen Therapy for Castration-Resistant Prostate Cancer: Initial Results

Sayman, Haluk; Gülşen, Fatih; Sağer, Sait; Akgün, Elife; Yeyin, Nami; Bilgiç, Seçkin; Toplutaş, Kübra Nur; An, Feifei; Beytur, Fatih; Öklü, Rahmi; Aras, Ömer

doi:10.1016/j.jvir.2021.10.016

Cited by 2 publications

(2 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…13 Nevertheless, early reports showed higher mean absorbed dose in metastatic prostate cancer lesions when 177 Lu PSMA was injected intra-arterially through the internal iliac arteries compared to the intravenous route. 14 Similar reports showed higher target absorbed dose when intra-arterial 177 Lu-high-affinity DOTATATE was used to treat refractory meningiomas, which are known to overexpress somatostatin receptors as well. 15 If intra-arterial administration of radiotheranostic therapies proves significant improvement in clinical outcomes and overall survival in specific clinical scenarios, then the IR role is likely to expand further in the near future.…”

Section: Ir Role In the Era Of Radiotheranosticsmentioning

confidence: 81%

Interventional Radiology in the Era of Radiotheranostics: An Update for Interventional Radiologists!

Elhelf

Clemenshaw

2022

Semin intervent Radiol

View full text Add to dashboard Cite

Section: Ir Role In the Era Of Radiotheranosticsmentioning

confidence: 81%

Interventional Radiology in the Era of Radiotheranostics: An Update for Interventional Radiologists!

Elhelf

Clemenshaw

2022

Semin intervent Radiol

View full text Add to dashboard Cite

“…Prostate cancer has been investigated as a target for both Y90 and IA delivery of radiotheranostics. Sayman et al compared the ratio of the absorbed dose of Lu-177-PSMA in prostate lesions compared to healthy organs in the IA and IV delivery techniques [43]. Four patients were given IV treatment one week before receiving the same therapy through IA delivery.…”

Section: Intra-arterial Delivery Of Radiopeptidesmentioning

confidence: 99%

Intra-Arterial Delivery of Radiopharmaceuticals in Oncology: Current Trends and the Future of Alpha-Particle Therapeutics

Kauffman

Morrison²,

O’Brien

et al. 2023

Pharmaceutics

View full text Add to dashboard Cite

A paradigm shift is underway in cancer diagnosis and therapy using radioactivity-based agents called radiopharmaceuticals. In the new strategy, diagnostic imaging measures the tumor uptake of radioactive agent “X” in a patient’s specific cancer, and if uptake metrics are realized, the patient can be selected for therapy with radioactive agent “Y”. The X and Y represent different radioisotopes that are optimized for each application. X–Y pairs are known as radiotheranostics, with the currently approved route of therapy being intravenous administration. The field is now evaluating the potential of intra-arterial dosing of radiotheranostics. In this manner, a higher initial concentration can be achieved at the cancer site, which could potentially enhance tumor-to-background targeting and lead to improved imaging and therapy. Numerous clinical trials are underway to evaluate these new therapeutic approaches that can be performed via interventional radiology. Of further interest is changing the therapeutic radioisotope that provides radiation therapy by β- emission to radioisotopes that also decay by α-particle emissions. Alpha (α)-particle emissions provide high energy transfer to the tumors and have distinct advantages. This review discusses the current landscape of intra-arterially delivered radiopharmaceuticals and the future of α-particle therapy with short-lived radioisotopes.

show abstract

Selective Intra-Arterial Lutetium-177-Labeled Prostate-Specific Membrane Antigen Therapy for Castration-Resistant Prostate Cancer: Initial Results

Cited by 2 publications

References 3 publications

Interventional Radiology in the Era of Radiotheranostics: An Update for Interventional Radiologists!

Interventional Radiology in the Era of Radiotheranostics: An Update for Interventional Radiologists!

Intra-Arterial Delivery of Radiopharmaceuticals in Oncology: Current Trends and the Future of Alpha-Particle Therapeutics

Contact Info

Product

Resources

About